Genomic Biomarkers: Role in personalized medicine and targeted therapies.

Genomic biomarkers are transforming cancer care by enabling precise, personalized treatment approaches. These biomarkers, derived from genetic, epigenetic, or molecular changes in tumors, help predict disease progression, treatment response, and patient outcomes. For instance, mutations in genes like EGFR or ALK in lung cancer guide the use of targeted therapies that block specific pathways, enhancing efficacy and reducing side effects. Biomarkers are also critical in identifying patients likely to benefit from immunotherapies, such as PD-L1 expression or microsatellite instability (MSI) status. Advances in high-throughput sequencing technologies have expanded the scope of biomarker discovery, allowing for the identification of novel targets and the development of companion diagnostics. As research progresses, integrating genomic biomarkers into routine clinical practice continues to refine therapeutic strategies, improve survival rates, and bring us closer to the promise of precision oncology.